2025-10-30T15:44:57-05:00 2024-12-31 951777440 GREEN HASSON & JANKS LLP 700 S FLOWER STREET SUITE 3300 LOS ANGELES CA 90017 990 2024-01-01 261636099 MELANOMA RESEARCH ALLIANCE FOUNDATION MELA 2023367230 730 15TH ST NW 4TH FLOOR WASHINGTON DC 20005 MARC HURLBERT CEO 2023367230 2025-10-29 1 1 LIZBETH G NEVAREZ P01399868 3108731600 2025-10-29 2024 2025-03-06 01:10:19Z MARC HURLBERT 730 15TH ST NW 4TH FLOOR WASHINGTON DC 20005 20606047 0 X WWW.CUREMELANOMA.ORG X 2007 DE TO ACCELERATE SCIENTIFIC DISCOVERY TO ELIMINATE SUFFERING AND DEATH DUE TO MELANOMA 26 25 16 44 0 0 8539530 15930736 0 0 905624 875240 -153456 -323271 9291698 16482705 6600342 13359283 0 0 1945290 1936596 0 0 755704 1770885 2150783 10316517 17446662 -1024819 -963957 24538655 25192749 11530586 13418906 13008069 11773843 TO END SUFFERING AND DEATH DUE TO MELANOMA BY COLLABORATING WITH ALL STAKEHOLDERS TO ACCELERATE POWERFUL RESEARCH, ADVANCE CURES FOR ALL PATIENTS, AND PREVENT MORE MELANOMAS. 0 0 15500754 13359283 THE MELANOMA RESEARCH ALLIANCE FOUNDATION ("MRA") SUPPORTS AMBITIOUS AND INNOVATIVE RESEARCH PROJECTS, SELECTED THROUGH PEER-REVIEW PANEL(S) AND INITIATED BY INDIVIDUAL SCIENTISTS AND SCIENCE RESEARCH TEAMS, TO PREVENT, DETECT AND TREAT MELANOMA. MRA CONVENES WORLD CLASS, CROSS-DISCIPLINARY GROUPS OF EXPERTS POSSESSING CLINICAL AND SCIENTIFIC EXPERTISE TO DEVELOP A RESEARCH AGENDA THAT WILL PROVIDE INNOVATIVE SOLUTIONS TO CRITICAL RESEARCH ISSUES LEADING TO MORE EFFECTIVE PREVENTION, EARLIER DETECTION AND BETTER TREATMENTS FOR MELANOMA. MRA MAKES GRANTS TO DOMESTIC AND FOREIGN RESEARCH UNIVERSITIES, MEDICAL SCHOOLS, AND NONPROFIT MEDICAL RESEARCH ORGANIZATIONS DIRECTLY INVOLVED IN DETERMINING THE CAUSES AND CURES OF MELANOMA ON THE CONDITION THAT SUCH RESEARCH BE MADE AVAILABLE TO THE SCIENTIFIC COMMUNITY. 560426 THE MRA OPERATES A PATIENT ENGAGEMENT PROGRAM THAT SUPPORTS INCREASED AWARENESS OF MELANOMA IN GENERAL, AND OF PREVENTION, DETECTION AND TREATMENT OPTIONS SPECIFICALLY. THE PATIENT ENGAGEMENT PROGRAM ALSO PROVIDES EDUCATION ABOUT AND PROMOTION OF CLINICAL TRIALS AND A PATIENT REGISTRY FOR RARE MELANOMAS. THE PATIENT ENGAGEMENT PROGRAM INCLUDES DEVELOPMENT AND DISTRIBUTION OF EDUCATIONAL MATERIALS, THE PROVISION OF EDUCATIONAL FORUMS, A CLINICAL TRIAL NAVIGATOR FOR PATIENTS AND AN ON-LINE PATIENT COMMUNITY. 16061180 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 18 0 1 16 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 26 25 1 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI MS X X MARC HURLBERT PHD 2023367230 730 15TH ST NW 4TH FLOOR WASHINGTON DC 20005 MICHAEL KLOWDEN DIRECTOR 0.30 40.00 X 0 39211 77922 DEBRA BLACK CHAIR/CO-FOUNDER 10.00 0.00 X X 0 0 0 EVAN BAYH DIRECTOR/SECRETARY 0.50 0.00 X X 0 0 0 LEON BLACK DIRECTOR/CO-FOUNDER 0.30 0.00 X 0 0 0 LEE ALPERT DIRECTOR 0.30 0.00 X 0 0 0 MARIA BELL DIRECTOR 0.30 0.00 X 0 0 0 BEN BLACK DIRECTOR 0.30 0.00 X 0 0 0 BARRY COHEN DIRECTOR 0.30 0.00 X 0 0 0 ELLEN DAVIS DIRECTOR 0.30 0.00 X 0 0 0 AMANDA EILIAN DIRECTOR 0.30 0.00 X 0 0 0 JASON FEDERICI DIRECTOR 0.30 0.00 X 0 0 0 JAMIE GERTZ DIRECTOR 0.30 0.00 X 0 0 0 DAISY HELMAN DIRECTOR 0.30 0.00 X 0 0 0 SUSAN HESS DIRECTOR 0.30 0.00 X 0 0 0 DENISE KELLEN DIRECTOR 0.30 0.00 X 0 0 0 NANCY MARKS DIRECTOR 0.30 0.00 X 0 0 0 MICHAEL MILKEN DIRECTOR 0.30 15.00 X 0 0 0 RICHARD RESSLER DIRECTOR 0.30 0.00 X 0 0 0 MARY JO ROGERS DIRECTOR 0.30 0.00 X 0 0 0 JEFFREY ROWBOTTOM DIRECTOR 0.30 0.00 X 0 0 0 IAN SCHUMAN DIRECTOR 0.30 0.00 X 0 0 0 JONATHAN SIMONS DIRECTOR 0.30 0.00 X 0 0 0 JONATHAN SOKOLOFF DIRECTOR 0.30 0.00 X 0 0 0 ELIZABETH STANTON DIRECTOR 0.30 0.00 X 0 0 0 SUZANNE TOPALIAN DIRECTOR 1.00 0.00 X 0 0 0 ERIC WEDEL DIRECTOR 0.30 0.00 X 0 0 0 JOHN HUNTER TREASURER 1.00 40.00 X 0 528790 97842 MARC HURLBERT CHIEF EXECUTIVE OFFICER 50.00 0.00 X 378565 0 35370 STEPHANIE KAUFFMAN PRESIDENT & COO 50.00 0.00 X 319388 0 68561 JOAN LEVY CHIEF SCIENCE OFFICER 40.00 0.00 X 243113 0 29980 TANISHA JACKSON SCIENTIFIC PROGRAM DIRECTO 40.00 0.00 X 104074 0 8680 JANINE RAUSCHER DIR. OF DEVELOPMENT OPERAT 40.00 0.00 X 108300 0 5662 1153440 568001 324017 5 0 1 0 KWT GLOBAL LLC ONE WORLD TRADE CENTER FLOOR 69 NEW YORK NY 10007 PR & COMMUNICATIONS 168301 1 87385 4084521 139484 11619346 549127 15930736 959300 959300 3599972 3678050 5982 -78078 -5982 -84060 -84060 113600 4084521 439310 -325710 -325710 OTHER INCOME 900099 2439 2439 2439 16482705 0 0 551969 11922010 11922010 1437273 1437273 1074977 645799 161740 267438 665036 399525 100060 165451 27103 16282 4078 6743 69096 41510 10396 17190 100384 60306 15104 24974 108781 108781 26015 26015 597840 478232 47250 72358 16687 14047 2134 506 82726 33031 18919 30776 219391 109798 48095 61498 90393 44835 10608 34950 449212 406755 36908 5549 449619 419653 7339 22627 29856 10285 6784 12787 DUES & SUBSCRIPTIONS 49329 16993 11209 21127 FILING FEES 13655 4704 3103 5848 RESEARCH MATERIALS 413 142 94 177 16866 11161 5705 17446662 16061180 629778 755704 779500 885078 12083212 12527521 2538036 2317764 165948 383080 8971945 9079249 14 57 24538655 25192749 184366 250042 10848720 12726845 497500 442019 11530586 13418906 X 10470033 9456079 2538036 2317764 13008069 11773843 24538655 25192749 X -963957 -76706 -193563 X X 0 1 X 1 0 X X X 1 THE MILKEN INSTITUTE 954240775 7 1 16061180 0 1 16061180 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 PART IV, SECTION A, LINE 6: THE AMOUNT OF SUPPORT REPORTED TO MILKEN INSTITUTE REPRESENTS ALL PROGRAMMATIC EXPENDITURES MADE TOWARDS ENDING SUFFERING AND DEATH DUE TO MELANOMA INCLUDING ISSUED GRANTS, TECHNICAL MANAGEMENT OF GRANTS PROGRAM AND PATIENT ENGAGEMENT. ALL OF THESE EXPENDITURES ADVANCE THE MISSION OF BOTH MRA AND THE MILKEN INSTITUTE. MRA PROVIDES DIRECT SUPPORT TO PUBLIC CHARITIES AND EDUCATIONAL INSTITUTIONS FOR THE PURPOSES OF CANCER RESEARCH SPECIFICALLY RELATED TO MELANOMA. SUPPORTING THESE UNRELATED RESEARCH ORGANIZATIONS DIRECTLY SUPPORTS THE MISSION OF THE MILKEN INSTITUTE SINCE PART OF THE INSTITUTE'S MISSION IS TO IMPROVE HEALTH WORLDWIDE. MRA ALSO PROVIDES PATIENT ENGAGEMENT AND EDUCATION RELATED TO MELANOMA TO IMPROVE AWARENESS OF MELANOMA AND ENGAGEMENT OF PATIENTS IN MELANOMA CLINICAL TRIALS. BY MRA PROVIDING THE GRANTS DIRECTLY TO THE CHARITIES AND EDUCATIONAL INSTITUTIONS, AND THROUGH PATIENT EDUCATION ACTIVITIES, MRA FURTHER ASSISTS THE MILKEN INSTITUTE. BECAUSE THERE IS A DIRECT LINE OF COMMUNICATION BETWEEN DONOR AND GRANT RECIPIENT, THE INSTITUTE CAN RELY ON MRA TO PROVIDE GRANT MONITORING AND GRANT SUPPORT SERVICES TO GRANT RECIPIENTS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 2000 2000 16059180 16061180 953059 238265 0 0 686207 900488 627659 953059 3167413 4751120 2000 2000 2000 6000 171552 225122 156915 238265 791854 1187781 0 X 16149618 -76706 112666 -343032 -307072 16456690 26015 26015 16482705 17383844 112666 -149469 -36803 17420647 26015 26015 17446662 PART X, LINE 2: MRA RECOGNIZES THE IMPACT OF TAX POSITIONS IN THE FINANCIAL STATEMENTS IF THAT POSITION IS MORE LIKELY THAN NOT TO BE SUSTAINED ON AUDIT, BASED ON THE TECHNICAL MERITS OF THE POSITION. DURING THE YEAR ENDED DECEMBER 31, 2024, MRA PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS AND DID NOT NOTE ANY MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR WHICH MIGHT HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. PART XI, LINE 2D - OTHER ADJUSTMENTS: LOSS ON WRITE-OFF OF UNCOLLECTIBLE PLEDGES RECEIVABLE -343,032. PART XII, LINE 2D - OTHER ADJUSTMENTS: DISCOUNT ON GRANTS -63,392. RETURN OF GRANTS TO OTHER ORGANIZATIONS -136,077. CY GRANT ADJUSTMENT 50,000. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 97273 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 150000 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 1055000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 135000 0 0 0 0 0 0 1437273 0 1437273 EUROPE (INCLUDING ICELAND & GREENLAND) NEXT STEPS: ADVANCING DRUG DISCOVERY TO IDENTIFY NEW THERAPIES 97273 WIRE 0 MIDDLE EAST AND NORTH AFRICA YOUNG INVESTIGATOR AWARD 255000 WIRE 0 MIDDLE EAST AND NORTH AFRICA TEAM SCIENCE AWARD 800000 WIRE 0 NORTH AMERICA NEXT STEPS: ADVANCING DRUG DISCOVERY TO IDENTIFY NEW THERAPIES 135000 WIRE 0 EAST ASIA AND THE PACIFIC DERMATOLOGY CAREER DEVELOPMENT AWARD 150000 WIRE 0 5 1 0 0 0 0 0 PART I, LINE 2: EACH PROPOSAL TO THE MRA IS REVIEWED FOR SCIENTIFIC MERIT AND TRANSLATIONAL AND CLINICAL IMPACT BY MRA'S WORLD-CLASS GRANT REVIEW COMMITTEE (GRC). CRITERIA ARE DESCRIBED IN THE MRA'S REQUEST FOR PROPOSALS. GRC MEMBERS ARE SENIOR THOUGHT-LEADERS IN MELANOMA AND CANCER RESEARCH. AFTER SCIENTIFIC PEER REVIEW BY THE GRC, THE MRA BOARD OF DIRECTORS APPROVES FINAL RESEARCH AWARDS FOR FUNDING. RESEARCH AWARD FUNDS ARE DISPENSED ON AN ANNUAL BASIS, CONTINGENT UPON MRA STAFF REVIEW OF ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS SUBMITTED BY THE GRANTEES. PART I, LINE 3: AWARDEES PROVIDE MRA WITH ANNUAL WRITTEN REPORTS OF THEIR RESEARCH PROGRESS AND COMPLIANCE WITH BUDGET GUIDELINES. FUNDS ARE DISTRIBUTED IN ANNUAL INSTALLMENTS AND NEXT YEAR'S INSTALLMENT IS NOT PROVIDED UNTIL SATISFACTORY REVIEW BY THE MRA CHIEF SCIENCE OFFICER AND SCIENTIFIC PROGRAM DIRECTOR. AWARDEES MUST KEEP SYSTEMATIC AND COMPLETE RECORDS ON THE RECEIPT AND DISBURSEMENT OF ALL AWARD FUNDS, AND MAY NOT COMMINGLE ANY FUNDS FROM OTHER SOURCES. PART IV, LINE 1 FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REQPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). LEVERAGED FINANCE FIGHT 4117871 4004271 113600 93000 93600 248419 MRA LIVE SALON ASPEN 80250 80250 4291 4198121 4084521 113600 93000 93600 252710 439310 -325710 1 AMERICAN SOCIETY FOR CLINICAL ONCOLOGY CONQUER CANCER FOUNDATION 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 25000 0 PARTNERSHIP AWARD BRIGHAM AND WOMEN'S HOSPITAL INC RESEARCH FINANCE C/O BANK OF AMERICA PO BOX 3149 BOSTON MA 02241 042312909 501(C)(3) 100000 0 PILOT AWARD CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BOULEVARD LOS ANGELES CA 90027 951690977 501(C)(3) 150000 0 NEXT STEPS: MELANOMA BIOMARKER DEVELOPMENT AWARD COLUMBIA UNIVERSITY IRVING MEDICAL CENTER 615 WEST 131ST STREET 3RD FLOOR NEW YORK NY 10027 135598093 501(C)(3) 1155000 0 1 TEAM SCIENCE AWARD, 1 YOUNG INVESTIGATOR AWARD DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 042263040 501(C)(3) 975000 0 1 TEAM SCIENCE AWARD, 1 NEXT STEPS: MELANOMA BIOMARKER DEVELOPMENT AWARD DREXEL UNIVERSITY 3201 ARCH STREET SUITE 400 PHILADELPHIA PA 19104 231352630 501(C)(3) 255000 0 YOUNG INVESTIGATOR AWARD DUKE UNIVERSITY PO BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 40000 0 MRA IN TRANSIT MELANOMA CONSORTIUM AWARD EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 255000 0 YOUNG INVESTIGATOR AWARD FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE N SEATTLE WA 98109 911935159 501(C)(3) 255000 0 YOUNG INVESTIGATOR AWARD H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 1155000 0 1 TEAM SCIENCE AWARD, 1 YOUNG INVESTIGATOR AWARD HENRY FORD HEALTH SYSTEM 2799 WEST GRAND BOULEVARD DETROIT MI 48202 381357020 501(C)(3) 100000 0 PILOT AWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 900000 0 TEAM SCIENCE AWARD JOHNS HOPKINS UNIVERSITY 3910 KESWICK ROAD N4327-B BALTIMORE MD 21211 520595110 501(C)(3) 264999 0 1 PARTNERSHIP AWARD, 1 PILOT AWARD, 1 NEXT STEPS: MELANOMA BIOMARKER DEVELOPMENT AWARD MASSACHUSETTS EYE AND EAR INFIRMARY 243 CHARLES STREET BOSTON MA 02114 042103591 501(C)(3) 149999 0 NEXT STEPS: MELANOMA BIOMARKER DEVELOPMENT AWARD MASSACHUSETTS GENERAL HOSPITAL (MASS GENERAL) 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 1025000 0 1 NEXT STEPS: ADVANCING DRUG DISCOVERY TO IDENTIFY NEW THERAPIES AWARD, 1 TEAM SCIENCE AWARD MEMORIAL SLOAN KETTERING CANCER CENTER (MSK) 1275 YORK AVENUE NEW YORK NY 100656007 131924236 501(C)(3) 1088210 0 2 PILOT AWARD, 1 TEAM SCIENCE AWARD NORTHWESTERN UNIVERSITY - CHICAGO CAMPUS 633 CLARK STREET EVANSTON IL 60208 362167817 501(C)(3) 125000 0 NEXT STEPS: ADVANCING DRUG DISCOVERY TO IDENTIFY NEW THERAPIES AWARD OREGON HEALTH & SCIENCE UNIVERSITY - OHSU 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 97239 931176109 PUBLIC UNIVERSITY 254842 0 YOUNG INVESTIGATOR AWARD SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 55 EAST WELLS STREET SUITE 1100 MILWAUKEE WI 53202 391554806 501(C)(3) 100000 0 PARTNERSHIP AWARD THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 485 BROADWAY MAIL CODE 8838 REDWOOD CITY CA 94063 941156365 501(C)(3) 900000 0 TEAM SCIENCE AWARD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10833 LE CONTE AVE FACTOR BLDG 11-260 LOS ANGELES CA 900951678 956006143 PUBLIC UNIVERSITY 627500 0 1 PILOT AWARD, 1 TEAM SCIENCE AWARD, 1 YOUNG INVESTIGATOR AWARD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 PUBLIC UNIVERSITY 1000000 0 1 TEAM SCIENCE AWARD, 1 PILOT AWARD THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER 333 COTTMAN AVENUE PHILADELPHIA PA 19111 236296135 501(C)(3) 255000 0 YOUNG INVESTIGATOR AWARD THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NC 275991350 566001393 PUBLIC UNIVERSITY 255000 0 YOUNG INVESTIGATOR AWARD THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 501(C)(3) 149460 0 DERMATOLOGY CAREER DEVELOPMENT AWARD THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19104 236434390 PUBLIC UNIVERSITY 100000 0 NEXT STEPS: ADVANCING DRUG DISCOVERY TO IDENTIFY NEW THERAPIES AWARD THOMAS JEFFERSON UNIVERSITY 833 CHESTNUT STREET SUITE 900 PHILADELPHIA PA 19107 231352651 501(C)(3) 100000 0 PILOT AWARD WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVENUE CB1034 ST LOUIS MO 63112 430653611 501(C)(3) 12000 0 TEAM SCIENCE AWARD YALE UNIVERSITY 2 WHITNEY AVENUE 6TH FLOOR NEW HAVEN CT 06510 060646973 501(C)(3) 150000 0 NEXT STEPS: MELANOMA BIOMARKER DEVELOPMENT AWARD 23 0 PART I, LINE 2: GRANTS ISSUED WITHIN THE UNITED STATES ARE SELECTED BASED ON SUBMISSIONS PROVIDED IN RESPONSE TO MRA REQUEST FOR PROPOSALS. APPLICANTS ARE REVIEWED FOR ELIGIBILITY - AND ELIGIBLE APPLICANTS ARE THEN REVIEWED BY PEER-SCIENTISTS, SCORED THROUGH THE PEER REVIEW PROCESS AND RANKED. APPLICATIONS MERITING AWARDS THROUGH PEER-REVIEW ARE THEN REVIEWED AGAINST EXISTING MRA PORTFOLIO AND FINAL SLATE OF PROPOSED GRANTS ARE MOVED TO THE FULL BOARD OF DIRECTORS FOR THEIR REVIEW PRIOR TO ISSUANCE. ALL GRANTEES, DOMESTIC AND INTERNATIONAL, ARE REQUIRED TO SUBMIT ANNUAL TECHNICAL PROGRESS REPORTS AND FINANCIAL REPORTS PRIOR TO RECEIVING THE NEXT YEAR OF FUNDING UNDER GRANT AGREEMENT. GRANTEES ARE ALSO INVITED TO PRESENT THEIR DATA AT MRA ANNUAL SCIENTIFIC RETREAT TO GATHER FEEDBACK/INPUT FROM PEERS AND PERIODIC SITE VISITS BY MRA STAFF WITH GRANTEES ARE CONDUCTED SOMETIMES VIA VIRTUAL AND OTHER TIMES IN PERSON VISITS. X X X 0 0 0 0 0 0 0 1 0 JOHN HUNTER TREASURER 0 424980 0 100000 0 3810 0 30500 0 67342 0 626632 0 0 MARC HURLBERT CHIEF EXECUTIVE OFFICER 358565 0 20000 0 0 0 16500 0 18870 0 413935 0 0 0 STEPHANIE KAUFFMAN PRESIDENT & COO 299388 0 20000 0 0 0 15532 0 53029 0 387949 0 0 0 JOAN LEVY CHIEF SCIENCE OFFICER 223113 0 20000 0 0 0 11252 0 18728 0 273093 0 0 0 PART I, LINE 7 EMPLOYEES WERE ELIGIBLE TO RECEIVE PERFORMANCE-BASED BONUSES. X 5 549127 FAIR MARKET VALUE 0 1 0 PART I, COLUMN (B): THE NUMBER OF CONTRIBUTORS ARE BEING REPORTED. FORM 990, PART VI, SECTION A, LINE 2 DEBRA BLACK, LEON BLACK AND BEN BLACK HAVE A FAMILY RELATIONSHIP. DEBRA BLACK AND RICHARD RESSLER HAVE A FAMILY RELATIONSHIP. JAMI GERTZ AND DEBRA BLACK HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 8B THERE IS NO EXECUTIVE COMMITTEE DURING THE YEAR. FORM 990, PART VI, SECTION B, LINE 11B MRA'S CEO, PRESIDENT & COO AND TREASURER REVIEW THE FORM 990. THE FINAL DRAFT IS DISTRIBUTED ELECTRONICALLY TO ALL THE BOARD MEMBERS BEFORE THE CEO SIGNS THE DOCUMENT AND IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C AS STATED IN THE MRA BYLAWS, EACH DIRECTOR, TRUSTEE, PRINCIPAL OFFICER, AND MEMBER OF A COMMITTEE OF THE BOARD IS TO SIGN A STATEMENT ANNUALLY AFFIRMING THEY HAVE RECEIVED THE CONFLICT OF INTEREST POLICY, THEY HAVE READ AND UNDERSTAND IT, AND THEY AGREE TO COMPLY WITH IT. UPON POTENTIAL CONFLICT OF INTERESTS, THE BOARD OR COMMITTEE WILL RESOLVE THE CONFLICT IN THE BEST INTEREST OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15 ACCORDING TO THE MRA BYLAWS, MEMBERS OF THE BOARD REVIEW AND APPROVE THE MRA CEO AND KEY EMPLOYEES SALARY TO ENSURE IT IS JUST AND REASONABLE. DURING THIS ANNUAL REVIEW, MEMBERS OF THE BOARD USE THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS FOR COMPARABLES. LINE 15B EXPLANATION: MEMBERS OF THE BOARD AND MRA LEADERSHIP CONDUCT AN ANNUAL REVIEW OF ITS COMPENSATION PHILOSOPHY AND UTILIZE COMPETITIVE BENCHMARKING DATA TO ENSURE COMPENSATION IS JUST AND REASONABLE. FORM 990, PART VI, SECTION C, LINE 19 MRA MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. A COPY OF FORM 990 AND THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. FORM 990, PART XI, LINE 9: LOSS ON WRITE-OFF OF UNCOLLECTIBLE PLEDGES RECEIVABLE -343,032. DISCOUNT ON GRANTS 63,392. RETURN OF GRANTS TO OTHER ORGANIZATIONS 136,077. GRANT ADJUSTMENT -50,000. FORM 990, PART XII, LINE 2C: NO PROCESSES HAVE CHANGED FROM THE PRIOR YEAR. MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA CA 90401 954240775 EDUCATIONAL, ECONOMIC RESEARCH, HEALTHCARE RESEARCH CA 501(C)(3) LINE 7 N/A 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0